Operating
Contingent consideration fair value adjustments
Over 4 years (FY 2021 to FY 2025), Contingent consideration fair value adjustments shows an upward trend with a -10.3% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2017
Last reportedQ4 2025Feb 11, 2026
How to read this metric
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
Detailed definition
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Peer comparison
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
Metric ID:
operating_business_combination_contingent_consideration__7f0be7Historical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | -$32.00M | $1.00M | $0.00 | $0.00 | -$10.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $336.00M | $0.00 | $15.00M |
| QoQ Change | — | — | — | +103.1% | -100.0% | — | — | +100.0% | — | — | — | — | — | — | — | — | — | -100.0% | — |
| YoY Change | — | — | — | — | — | — | +68.8% | -100.0% | — | — | +100.0% | — | — | — | — | — | — | — | — |
Range-$32.00M – $336.00M
Avg YoY Growth+22.9%
Median YoY Growth+68.8%
Contingent consideration fair value adjustments at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's contingent consideration fair value adjustments?
- Bristol-Myers Squibb (BMY) reported contingent consideration fair value adjustments of $15.00M in Q4 2025.
- What is the long-term trend for Bristol-Myers Squibb's contingent consideration fair value adjustments?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's contingent consideration fair value adjustments has grown at a -10.3% compound annual growth rate (CAGR), from -$542.00M to $351.00M.
- What does contingent consideration fair value adjustments mean?
- Changes in the estimated cost of future payments owed to sellers of acquired companies based on performance milestones.